Xuan Zhang

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 12

Top Venues

Nature communications

Journal of medicinal chemistry

Future medicinal chemistry

Oncogene

University of Florida

East China Normal University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Florida

United States

Research Assistant Professor :: Medicinal Chemistry

University of Florida

United States

Postdoctoral Associate :: Medicinal Chemistry

University of Arkansas for Medical Sciences

United States

Postdoctoral fellow :: College of Pharmacy

University of Arkansas for Medical Sciences

United States

Research Technician :: College of Pharmacy

Shanghai Institute of Materia Medica Chinese Academy of Sciences

China

Research fellow

Education History

East China Normal University

China

PHD

Publications

Li Hu, Chanjuan Dong, Zhe Wang, Shengyuan He, Yiwen Yang, Meiting Zi, Huiqin Li, Yanghuan Zhang, Chuanjie Chen, Runzi Zheng, Shuting Jia, Jing Liu, Xuan Zhang, Yong-Han He
A rationally designed fluorescence probe achieves highly specific and long-term detection of senescence in vitro and in vivo. Aging cell (2023)
Chuanjie Chen, Yiwen Yang, Zhe Wang, Huiwen Li, Chanjuan Dong, Xuan Zhang
Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity. Journal of medicinal chemistry (2023)
Dong-Wen Lv, Pratik Pal, Xingui Liu, Yannan Jia, Dinesh Thummuri, Peiyi Zhang, Wanyi Hu, Jing Pei, Qi Zhang, Shuo Zhou, Sajid Khan, Xuan Zhang, Nan Hua, Qingping Yang, Sebastian Arango, Weizhou Zhang, Digant Nayak, Shaun K Olsen, Susan T Weintraub, Robert Hromas, Marina Y Konopleva, Yaxia Yuan, Guangrong Zheng, Daohong Zhou
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nature communications 12 (1) (2021)
Yufeng Xiao, Jia Wang, Lisa Y Zhao, Xinyi Chen, Guangrong Zheng, Xuan Zhang, Daiqing Liao
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs. Chemical communications (Cambridge, England) 56 (68) (2021)
Ryan Kolb, Umasankar De, Sajid Khan, Yuewan Luo, Myung-Chul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang, Xuan Zhang, Nicholas Borcherding, Daniel Koppel, Yang-Xin Fu, Song Guo Zheng, Dorina Avram, Guangrong Zheng, Daohong Zhou, Weizhou Zhang
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nature communications 12 (1) (2021)
Xuan Zhang, Xingui Liu, Daohong Zhou, Guangrong Zheng
Targeting anti-apoptotic BCL-2 family proteins for cancer treatment. Future medicinal chemistry 12 (7) (2020)
Xingui Liu, Xuan Zhang, Dongwen Lv, Yaxia Yuan, Guangrong Zheng, Daohong Zhou
Assays and technologies for developing proteolysis targeting chimera degraders. Future medicinal chemistry 12 (12) (2020)
Yong-Han He, Xuan Zhang, Jianhui Chang, Ha-Neui Kim, Peiyi Zhang, Yingying Wang, Sajid Khan, Xingui Liu, Xin Zhang, Dong-Wen Lv, Lin Song, Wen Li, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand, Yuma T Ortiz, Vivekananda Budamagunta, Jennifer H Elisseeff, Judith Campisi, Maria Almeida, Guangrong Zheng, Daohong Zhou
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nature communications 11 (1) (2020)
Peiyi Zhang, Xuan Zhang, Xingui Liu, Sajid Khan, Daohong Zhou, Guangrong Zheng
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors. Exploration of targeted anti-tumor therapy 1 (2020)
Sajid Khan, Yonghan He, Xuan Zhang, Yaxia Yuan, Shaoyan Pu, Qing-Peng Kong, Guangrong Zheng, Daohong Zhou
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics. Oncogene 39 (26) (2020)
Sajid Khan, Xuan Zhang, Dong-Wen Lv, Qi Zhang, Yonghan He, Peiyi Zhang, Xingui Liu, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand, Jing Pei, Weizhou Zhang, Abhisheak Sharma, Christopher R McCurdy, Vinitha M Kuruvilla, Natalia Baran, Adolfo A Ferrando, Yong-Mi Kim, Anna Rogojina, Peter J Houghton, Guangcun Huang, Robert Hromas, Marina Konopleva, Guangrong Zheng, Daohong Zhou
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature medicine 25 (12) (2019)
Sun Hee Moon, Xuan Zhang, Guangrong Zheng, Daniel G Meeker, Mark S Smeltzer, En Huang
Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. Journal of medicinal chemistry 60 (23) (2017)

Xuan Zhang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Xuan Zhang